Via Facsimile and U.S. Mail
Mail Stop 03-09

										February 22,
2005

Mark McDade
Chief Executive Officer
Protein Design Labs, Inc.
34801 Campus Drive
Fremont, California 94555

Re:	Protein Design Labs, Inc.
	Registration Statement on Form S-3
      Filed February 11, 2005
	File Number 333-122760

Dear Mr. McDade:

      This is to advise you that we have undertaken a limited
review
of the above referenced registration statement to resolution of
your
pending confidential treatment request and the following comments
herein.  After any issues that arise during our examination of the
request have been satisfied, we will consider your request for
acceleration of the effective date of the registration statement.

      Where indicated, we think you should revise your document in
response to these comments.  If you disagree, we will consider
your
explanation as to why our comment is inapplicable or a revision is
unnecessary.  Please be as detailed as necessary in your
explanation.
In some of our comments, we may ask you to provide us with
supplemental information so we may better understand your
disclosure.
After reviewing this information, we may or may not raise
additional
comments.

      The purpose of our review process is to assist you in your
compliance with the applicable disclosure requirements and to
enhance
the overall disclosure in your filing.  We look forward to working
with you in these respects.  We welcome any questions you may have
about our comments or on any other aspect of our review.  Feel
free
to call us at the telephone numbers listed at the end of this
letter.


1. Please confirm whether the shares being registered have already
been issued or will be issued upon the closing of your acquisition
of
ESP Pharma Holding Company, Inc., for the selling shareholders
identified in the registration statement.
2. If the shares being registered for resale will be issued upon
closing of the acquisition, supplementally, please explain why
this
registration is not premature.
3. Please be advised that you will need to file your Form 10-K for
the year ended December 31, 2004, and amend your registration
statement to incorporate it by reference, before we will consider
your request for acceleration of the effective date of the
registration statement.

*	*	*

      As appropriate, please amend your registration statement in
response to these comments.  You may wish to provide us with
marked
copies of the amendment to expedite our review.  Please furnish a
cover letter with your amendment that keys your responses to our
comments and provides any requested supplemental information.
Detailed cover letters greatly facilitate our review.  Please
understand that we may have additional comments after reviewing
your
amendment and responses to our comments.

      We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to
be
certain that they have provided all information investors require
for
an informed decision.  Since the company and its management are in
possession of all facts relating to a company`s disclosure, they
are
responsible for the accuracy and adequacy of the disclosures they
have made.

	Notwithstanding our comments, in the event the company
requests
acceleration of the effective date of the pending registration
statement, it should furnish a letter, at the time of such
request,
acknowledging that:

* should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;
* the action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does not
relieve the company from its full responsibility for the adequacy
and
accuracy of the disclosure in the filing; and
* the company may not assert this action as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

	In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division of Corporation Finance in connection with our review of
your
filing or in response to our comments on your filing.

      We will consider a written request for acceleration of the
effective date of the registration statement as a confirmation of
the
fact that those requesting acceleration are aware of their
respective
responsibilities under the Securities Act of 1933 and the
Securities
Exchange Act of 1934 as they relate to the proposed public
offering
of the securities specified in the above registration statement.
We
will act on the request and, pursuant to delegated authority,
grant
acceleration of the effective date.

      We direct your attention to Rules 460 and 461 regarding
requesting acceleration of a registration statement.  Please allow
adequate time after the filing of any amendment for further review
before submitting a request for acceleration.  Please provide this
request at least two business days in advance of the requested
effective date.

      Please contact Albert Lee at (202) 824-5522 or me at (202)
942-
1840 with any questions.

      Sincerely,



								Jeffrey P. Riedler
								Assistant Director

cc:	J. Howard Clowes
	DLA Piper Rudnick Gray Cary US LLP
	153 Townsend Street, Suite 800
	San Francisco, CA 94107

??

??

??

??

Mark McDade
Protein Design Labs, Inc.
Page 1